Clinical Trial Update: NRX-101 for Bipolar Depression With Subacute Suicidal Ideation [Phase 2, Phase 3]

View source ↗

Summary

NRX-101 for bipolar depression with subacute suicidal ideation has completed Phase 2/3 testing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder Depressive Episode

Drugs mentioned

• NRX-101 (dextromethorphan/quinidine)

Snippet

Sponsor: NeuroRx, Inc. | Conditions: Bipolar Depression, Suicidal Ideation and Behavior | Phase 2, Phase 3 | Status: COMPLETED